5-MeO-DALT
 | |
| Systematic (IUPAC) name | |
|---|---|
|
N-allyl-N-[2-(5-methoxy -1H-indol-3-yl)ethyl] prop-2-en-1-amine | |
| Clinical data | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
928822-98-4  |
| PubChem | CID 50878551 |
| ChemSpider |
21106245  |
| Chemical data | |
| Formula | C17H22N2O |
| Molar mass | 270.375 g/mol |
| |
| |
| (what is this?) (verify) | |
5-MeO-DALT or N,N-di allyl-5-methoxy tryptamine is a psychedelic tryptamine first synthesized by Alexander Shulgin.
Chemistry
The full name of the chemical is N-allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl] prop-2-en-1- amine. It is related to the compounds 5-MeO-DPT and DALT.
Pharmacology
5-MeO-DALT binds to 5-HT1A, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, α2A, α2B, α2C, H1, κ-opioid, σ1 and σ2 receptors with Ki values lower than 10μM and also acts as a DAT and SERT monoamine reuptake inhibitor.[1]
| Binding site | pKi ± SEM at binding site |
| 5-HT1A | 7.70 ± 0.10 |
| 5-HT1B | 6.13 ± 0.04 |
| 5-HT1D | 7.00 ± 0.10 |
| 5-HT1E | 6.30 ± 0.05 |
| 5-HT2A | 6.66 ± 0.08 |
| 5-HT2B | 7.23 ± 0.05 |
| 5-HT2C | 6.34 ± 0.08 |
| 5-HT5A | 5.48 ± 0.04 |
| 5-HT6 | 6.81 ± 0.03 |
| 5-HT7 | 7.05 ± 0.07 |
| α2A | 6.67 ± 0.07 |
| α2B | 6.14 ± 0.04 |
| α2C | 5.83 ± 0.06 |
| H1 | 6.30 ± 0.06 |
| H3 | 5.77 ± 0.04 |
| κOR | 5.95 ± 0.07 |
| μOR | > 5.00 |
| σ1 | 6.52 ± 0.06 |
| σ2 | 6.60 ± 0.05 |
| DAT | 5.50 ± 0.20 |
| NET | > 5.00 |
| SERT | 6.30 ± 0.05 |
The metabolism and cytochrome P450 inhibition of 5-MeO-DALT has been described in scientific literature.[2][3]
History
The first material regarding the synthesis and effects of 5-MeO-DALT was sent from Alexander Shulgin to a research associate named Murple in May 2004, after which it was circulated online. In June 2004 5-MeO-DALT became available from internet research chemical vendors after being synthesized by commercial laboratories in China. In August 2004 the synthesis and effects of 5-MeO-DALT were published by Erowid.[4]
Dosage
Doses ranging from 12–20 mg were tested by Alexander Shulgin's research group.[5]
Side effects
There is no published literature on the toxicity of 5-MeO-DALT.
Legal Status
China
As of October 2015 5-MeO-DALT is a controlled substance in China.[6]
Japan
5-MeO-DALT became a controlled substance in Japan from April 2007, by amendment to the Pharmaceutical Affairs Law.[7]
United Kingdom
5-MeO-DALT became a Class A drug in the UK on January 7th 2015 after an update to the tryptamine blanket ban.
Singapore
5-MeO-DALT is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[8]
Sweden
Sveriges riksdag added 5-MeO-DALT to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of May 1, 2012, published by Medical Products Agency in their regulation LVFS 2012:6 listed as 5-MeO-DALT N-allyl-N-[2-(5-metoxi-1H-indol-3-yl)etyl]-prop-2-en-1-amin.[9]
United States
5-MeO-DALT is not scheduled at the federal level in the United States,[10] but it is likely that it could be considered an analog of 5-Meo-DiPT or another tryptamine, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.
Florida
5-MeO-DALT is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.[11]
Louisiana
5-MeO-DALT is a Schedule I controlled substance in the state of Louisiana making it illegal to buy, sell, or possess in Louisiana.[12]
Notes
- ↑ Nicholas V. Cozzi, Paul F. Daley (December 2015). "Receptor binding profiles and quantitative structure-affinity relationships of some 5–substituted-n,n-diallyltryptamines". Bioorganic & Medicinal Chemistry Letters. doi:10.1016/j.bmcl.2015.12.053.
- ↑ Julian A. Michely, Andreas G. Helfer, Simon D. Brandt, Markus R. Meyer, Hans H. Maurer (August 2015). "Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC–MS, LC–MS n , and LC–HR–MS–MS". Analytical and Bioanalytical Chemistry 407: 7831–42. doi:10.1007/s00216-015-8955-0. PMID 26297461.
- ↑ Julia Dinger, Campbell Woods, Simon D. Brandt, Markus R. Meyer, Hans H. Maurer (January 2016). "Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class". Toxicology Letters 241: 82–94. doi:10.1016/j.toxlet.2015.11.013. PMID 26599973.
- ↑ Hamilton Morris, Ash Smith (2 May 2010). "The Last Interview With Alexander Shulgin". Vice. Retrieved 3 September 2015.
- ↑ "Sasha Shulgin - 5-MeO-DALT, 2C-B-FLY & 5-EtOs". Retrieved 3 September 2015.
- ↑ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
- ↑ "厚生労働省：平成１8年度無承認無許可医薬品等買上調査の結果について" (in Japanese). Retrieved 24 July 2015.
- ↑ "CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Retrieved 24 July 2015.
- ↑ Generaldirektör Christina Rångemark Åkerman (20 April 2012). "Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika" (PDF) (in Swedish). Retrieved 3 September 2015.
- ↑ §1308.11 Schedule I.
- ↑ Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL
- ↑ "Louisiana State Legislature". Retrieved 3 September 2015.
External links
| ||||||||||||||||||
| ||||||